SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial SPVN20 aims to…
Our Company
Moving beyond single gene correction therapies to deliver new treatments.
We are a clinical-stage genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments to patients affected by blinding retinal diseases, regardless of genetic cause.
Genomic Medicines
Our goal is to harness the potential of gene therapy to bring cutting-edge innovation into ocular disease drug discovery and development.
Pipeline
At the heart of this is a pipeline of mutation independent treatments for Inherited Retinal Diseases (IRD) such as Retinitis Pigmentosa (RP), as well as dry AMD and Geographic Atrophy (GA).
Retinitis Pigmentosa
A group of IRDs which are a leading cause of blindness globally. Current treatment approaches are not applicable to all patients, regardless of genetic background or disease stage. With our comprehensive approach for RP, we believe that we can bring meaningful differences to most of them.
SPVN06
SparingVision’s lead product, SPVN06, is a breakthrough gene therapy approach targeting Inherited Retinal Diseases (IRDs).
Learn More
Combining 20+ years of world-leading ophthalmic research with a world class team of experts from across the international drug development spectrum. SparingVision has an unparalleled understanding of retinal disease and bringing novel treatments to patients.
Investors
Public Funding
